Compare IVA & PSEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IVA | PSEC |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2020 | 2012 |
| Metric | IVA | PSEC |
|---|---|---|
| Price | $4.70 | $2.26 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 10 | 1 |
| Target Price | ★ $16.20 | $2.50 |
| AVG Volume (30 Days) | 641.2K | ★ 4.0M |
| Earning Date | 03-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 20.07% |
| EPS Growth | N/A | ★ 104.44 |
| EPS | N/A | ★ 0.06 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $751.20 | N/A |
| P/E Ratio | ★ N/A | $38.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.35 | $2.11 |
| 52 Week High | $7.98 | $3.13 |
| Indicator | IVA | PSEC |
|---|---|---|
| Relative Strength Index (RSI) | 52.02 | 50.97 |
| Support Level | $4.46 | $2.15 |
| Resistance Level | $4.70 | $2.33 |
| Average True Range (ATR) | 0.16 | 0.06 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 43.40 | 43.75 |
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests mainly in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.